Does Inovio Pharmaceuticals (NASDAQ:INO) Look Attractive Now? Citigroup Initiates Coverage

December 7, 2017 - By Michael Collier

 Does Inovio Pharmaceuticals (NASDAQ:INO) Look Attractive Now? Citigroup Initiates Coverage

Why Has Citigroup Given Inovio Pharmaceuticals (NASDAQ:INO) a $10.0 Price Target

New York: Inovio Pharmaceuticals (NASDAQ:INO) coverage was initiated with a key ‘Buy’ rating as well as a $10.0 target price per share at Citigroup. The TP by Citigroup indicates upside of 128.31 % from the last price.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Ratings Coverage

Among 8 analysts covering Inovio Pharmaceuticals (NASDAQ:INO), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Inovio Pharmaceuticals has $31 highest and $9 lowest target. $14.33’s average target is 227.17% above currents $4.38 stock price. Inovio Pharmaceuticals had 34 analyst reports since August 10, 2015 according to SRatingsIntel. The stock of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has “Buy” rating given on Thursday, June 8 by Aegis Capital. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, September 12. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, November 9 report. The firm earned “Buy” rating on Wednesday, September 6 by Citigroup. The rating was maintained by Piper Jaffray with “Overweight” on Monday, August 10. On Wednesday, August 9 the stock rating was maintained by Maxim Group with “Buy”. H.C. Wainwright maintained the shares of INO in report on Friday, July 7 with “Buy” rating. The stock has “Buy” rating by H.C. Wainwright on Tuesday, November 28. The company was downgraded on Tuesday, August 9 by Maxim Group. H.C. Wainwright maintained it with “Buy” rating and $13.0 target in Friday, October 6 report.

It closed at $4.38 lastly. It is down 29.01% since December 7, 2016 and is downtrending. It has underperformed by 45.71% the S&P500.

Analysts await Inovio Pharmaceuticals, Inc. (NASDAQ:INO) to report earnings on March, 21. They expect $-0.29 earnings per share, up 19.44 % or $0.07 from last year’s $-0.36 per share. After $-0.40 actual earnings per share reported by Inovio Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -27.50 % EPS growth.

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. The company has market cap of $395.50 million. The Company’s SynCon immunotherapy design has the ability to break the immune systemÂ’s tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It currently has negative earnings. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus.

More recent Inovio Pharmaceuticals, Inc. (NASDAQ:INO) news were published by: Globenewswire.com which released: “Inovio Pharmaceuticals Appoints Wendy Yarno To its Board of Directors” on December 06, 2017. Also Globenewswire.com published the news titled: “Inovio Pharmaceuticals SynCon® TERT Cancer Immunotherapy Combined with …” on November 27, 2017. Fool.com‘s news article titled: “Why Inovio Pharmaceuticals Inc. Is Sinking Today” with publication date: November 09, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.